Literature DB >> 11923145

Protein conjugate pneumococcal vaccines.

Vana Spoulou, Charles F Gilks, John P A Ioannidis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11923145      PMCID： PMC1122694          DOI： 10.1136/bmj.324.7340.750

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

Review 1.  Pneumococcal conjugate vaccines.

Authors:  J Eskola; M Anttila
Journal:  Pediatr Infect Dis J       Date:  1999-06       Impact factor: 2.129

2.  Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era.

Authors:  K A Robinson; W Baughman; G Rothrock; N L Barrett; M Pass; C Lexau; B Damaske; K Stefonek; B Barnes; J Patterson; E R Zell; A Schuchat; C G Whitney
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

3.  Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults.

Authors:  J B Rubins; A K Puri; J Loch; D Charboneau; R MacDonald; N Opstad; E N Janoff
Journal:  J Infect Dis       Date:  1998-08       Impact factor: 5.226

4.  Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.

Authors:  T A Lieu; G T Ray; S B Black; J C Butler; J O Klein; R F Breiman; M A Miller; H R Shinefield
Journal:  JAMA       Date:  2000-03-15       Impact factor: 56.272

5.  23-valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.

Authors:  N French; J Nakiyingi; L M Carpenter; E Lugada; C Watera; K Moi; M Moore; D Antvelink; D Mulder; E N Janoff; J Whitworth; C F Gilks
Journal:  Lancet       Date:  2000-06-17       Impact factor: 79.321

6.  Haemophilus influenzae type b disease: impact and effectiveness of diphtheria-tetanus toxoids-acellular pertussis (-inactivated poliovirus)/H. influenzae type b combination vaccines.

Authors:  H J Schmitt; R von Kries; B Hassenpflug; M Hermann; A Siedler; W Niessing; R Clemens; J Weil
Journal:  Pediatr Infect Dis J       Date:  2001-08       Impact factor: 2.129

7.  Immunogenicity and tolerance of a 7-valent pneumococcal conjugate vaccine in nonresponders to the 23-valent pneumococcal vaccine.

Authors:  S Zielen; I Bühring; N Strnad; J Reichenbach; D Hofmann
Journal:  Infect Immun       Date:  2000-03       Impact factor: 3.441

8.  Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.

Authors:  K L O'Brien; A J Swift; J A Winkelstein; M Santosham; B Stover; R Luddy; J E Gootenberg; J T Nold; A Eskenazi; S J Snader; H M Lederman
Journal:  Pediatrics       Date:  2000-11       Impact factor: 7.124

9.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Authors:  J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

10.  Comparison of the safety and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected children.

Authors:  J C King; P E Vink; J J Farley; M Parks; M Smilie; D Madore; R Lichenstein; F Malinoski
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.